Call us 24/7

Clinical trials

Filters

33 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).

This is an open-label, nonrandomized, phase 1 dose escalation, dose expansion, and phase 2 study targeting tumors with FGF/FGFR aberrations. The purpose of the study is to evaluate the safety, tolerability, PK, pharmacodynamic, and anti-tumor activity of TAS-120 in patients with advanced solid tumors with and without FGF/FGFR-related abnormalities.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves overall response rate and whether the combination of pevonedistat and azacitidine improves event-free survival when compared with single-agent azacitidine.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase II, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in up to 174 patients with NSCLC exon 20 insertion mutations (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon 20 insertion mutations).

 
   

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to evaluate the efficacy and safety of intrapleural dornase alfa and tPA administered to participants with clinical failure of small-bore chest tube with persistent pleural effusions or malignancy-related loculated effusion to improve pleural drainage.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study examines the efficacy of Debio 1347 administered at the recommended Phase II dose of 80 mg in subjects with solid tumors harboring FGFR1-3 gene fusion/rearrangement. The study will include 3 cohorts of subjects comprising biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and, in Cohort 3, all other solid tumor histologies not included in Cohorts 1-2, such as non-small cell lung cancer (NSCLC), head and neck cancer, thyroid cancer, oral cancer, breast cancer, prostate cancer and others but excluding primary brain tumors.